Sponsor: educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd and Lilly
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, CLL, Diseases, Lymphoid Malignancies
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, CLL, Diseases, Lymphoid Malignancies
Friday, December 6, 2024: 7:00 AM-10:00 AM
Seaport Ballroom EFGH
(Manchester Grand Hyatt San Diego)
Chair:
Jeff P. Sharman, MD, Willamette Valley Cancer Institute, Sarah Cannon Research
Disclosures:
Sharman: Eli Lilly and Company: Consultancy, Honoraria, Other: Anciliarry supplies, transportation, Research Funding; BMS: Consultancy, Research Funding; Merck: Consultancy, Research Funding; Pharmacyclics LLC, an AbbVie Company: Honoraria; BeiGene: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Genmab: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; TG Therapeutics: Honoraria; ADC Therapeutics: Honoraria; AbbVie: Consultancy, Honoraria, Research Funding.
Speakers:
Kerry A. Rogers, MD, The Ohio State University
,
William G. Wierda, The University of Texas MD Anderson Cancer Center
,
Farrukh T. Awan, MD, UT Southwestern Medical Center
and
Bita Fakhri, MD, MPH, ARRAY(0xee61ca8)
Disclosures:
Rogers: AbbVie Inc, Genentech, a member of the Roche Group, Novartis: Research Funding; Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company: Membership on an entity's Board of Directors or advisory committees; AbbVie Inc, BeiGene Ltd, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pharmacyclics LLC, an AbbVie Company: Consultancy; AstraZeneca Pharmaceuticals LP.: Membership on an entity's Board of Directors or advisory committees. Wierda: Eli Lilly: Research Funding; AbbVie: Research Funding; Gilead Sciences: Research Funding; Nurix Therapeutics: Research Funding; Oncternal Therapeutics: Research Funding; Loxo Oncology: Research Funding; Cyclacel Pharmaceuticals Inc: Research Funding; Genentech, Inc.: Research Funding; BMS: Research Funding; Pharmacyclics LLC, an AbbVie Company: Research Funding; AstraZeneca: Research Funding; Acerta Pharma: Research Funding; Oncternal Therapeutics: Research Funding; Novartis: Research Funding; Kite: Research Funding; GSK: Research Funding; F. Hoffmann-La Roche Ltd.: Research Funding; Janssen: Research Funding; Juno Therapeutics: Research Funding; National Comprehensive Care Center (NCCN): Other: Financial relationship (Chair, CLL); Numab Therapeutics: Research Funding; Accutar Biotechnology: Research Funding. Awan: Genmab: Consultancy; Adaptive Biotechnologies: Consultancy; BMS: Consultancy; BeiGene: Consultancy; AstraZeneca: Consultancy; Dava Oncology: Consultancy; Loxo Oncology: Consultancy; AbbVie/Pharmacyclics: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Incyte: Consultancy. Fakhri: AbbVie, ADC therapeutics, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie/Genmab, Loxo-Lilly, BMS, Angiocrine: Research Funding; Loxo/Lilly: Research Funding.
This 2-hour CME-accredited activity – offered to both in-person and virtual attendees – will focus on the management of patients with chronic lymphocytic leukemia (CLL). Five clinical investigators will serve as faculty for the program, one of whom will moderate. To create a relevant agenda, prior to the symposium Research To Practice (RTP) will recruit 50 general medical oncologists/hematologists to complete a survey designed to evaluate their educational interests and knowledge deficiencies related to the treatment of CLL. During the symposium, selected results from the survey highlighting areas of greatest interest will be presented. The faculty members will then review relevant research findings, discuss evidence-based treatment approaches and provide perspectives on ongoing studies. Actual questions contributed by the survey respondents as well as audience members will be integrated into the proceedings. The live activity will be recorded and developed into an enduring CME resource and promoted by RTP to 46,500 subscribers worldwide.
See more of: Friday Satellite Symposia